Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Nu Holdings
NU
5
Liberty Latin America-A
LILA
CN Stock MarketDetailed Quotes
603669 Lionco Pharmaceutical Group
- 4.44
- -0.18-3.90%
Noon Break Apr 25 11:29 CST
3.20BMarket Cap-24.53P/E (TTM)
4.55High4.39Low274.30KlotVolume4.53Open4.62Pre Close121.87MTurnover3.80%Turnover RatioLossP/E (Static)721.24MShares9.5452wk High4.52P/B3.20BFloat Cap3.4552wk Low5.08Limit Up721.24MShs Float20.05Historical High4.16Limit Down3.46%Amplitude2.94Historical Low--Dividend TTM4.44Avg Price112.03KlotAsk--Div YieldTTM100Lot Size142.37KlotBid
Lionco Pharmaceutical Group News
Insider Information Insider Registration Management System (Revised in April 2025)
General Manager Work Rules (Revised April 2025)
Rules of work for board secretaries (revised in April 2025)
Fund Raising Management System (Revised in April 2025)
CITIC Securities Co., Ltd.\'s inspection opinions on the storage and use of funds raised by Lingkang Pharmaceutical Group Co., Ltd. in 2024
Special inspection report on the 2024 operating income deduction table of Lingkang Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the 27th Meeting of the Fourth Board of Directors
Verification report on the storage and actual use of funds raised by Lingkang Pharmaceutical Group Co., Ltd.
Special report on the annual storage and use of raised funds
Lingkang Pharmaceutical Group Co., Ltd.\'s evaluation report on accounting firms
Report of the Audit Committee of the Board of Directors of Lingkang Pharmaceutical Group Co., Ltd. on the performance evaluation of the accounting firm
Special Opinions of the Board of Directors of Lingkang Pharmaceutical Group Co., Ltd. on the 2024 Independence Assessment of Independent Directors
Independent Director\'s 2024 Annual Debriefing Report - Pan Ziqiang
Independent Director\'s 2024 Annual Debriefing Report-Before
Report on the performance of the Audit Committee of the Board of Directors of the Company in 2024
Internal Control Audit Report of Lingkang Pharmaceutical Group Co., Ltd.
2024 Internal Control Evaluation Report
Independent Director\'s 2024 Annual Debriefing Report - He Chao
Special audit report on the summary table of non-operating capital occupation and other related capital transactions of Lingkang Pharmaceutical Group Co., Ltd.
2024 Annual Audit Report
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs